Dus symptoombestrijding heeft geen zin als de voedingsbodem niet gezond is
GLP-1 drugs likely to be helpful for additional indications October 22, 2025 Summary: New GLP-1 and related drugs are likely to become available over the next 3-5 years, and this drug class will likely be approved for additional indications
Cardiometabolic markers (TRIUMPH-1, 80 weeks) This profile reads more like metabolic reprogramming than appetite suppression: Triglycerides: 41.0% Non-HDL cholesterol: 24.2% Systolic blood pressure: 12.3 mmHg Waist circumference: 24.1 cm (9.5 inches) What to Watch For: The Most Common Side Effects Retatrutides safety profile is broadly consistent with the GLP-1 class, with one genuinely new signal
Extension studies have followed patients for multiple years with continued efficacy and safety
Consultation is $99, and $49 may be applied toward your program if you move forward
While the exact mechanism is not fully understood, clinical data consistently shows lower nausea rates with tirzepatide (25-33%) compared to semaglutide (44%) despite greater overall weight loss
